Challenges and Rewards Part 1

  • Valentino J. Stella
  • Ronald T. Borchardt
  • Michael J. Hageman
  • Reza Oliyai
  • Hans Maag
  • Jefferson W. Tilley

Part of the Biotechnology: Pharmaceutical Aspects book series (PHARMASP, volume V)

Table of contents

  1. Front Matter
    Pages i-xvii
  2. A Case for Prodrugs

    1. Front Matter
      Pages 1-1
    2. Valentino J. Stella
      Pages 3-33
  3. Problems Addressable by Prodrugs

    1. Front Matter
      Pages 35-35
    2. Permeability

      1. Kenneth B. Sloan, Scott C. Wasdo
        Pages 83-123
      2. Tomi Järvinen, Riku Niemi
        Pages 125-155
    3. Solubility

      1. Tycho Heimbach, David Fleisher, Amal Kaddoumi
        Pages 157-215
      2. Jeffery Hemenway, Valentino J. Stella
        Pages 217-281
    4. Metabolism

      1. Bruce J. Aungst, Nicole Matz
        Pages 339-355
    5. Controlled Release

      1. Jaymin C. Shah
        Pages 357-377
      2. Claus Larsen, Jesper Østergaard, Susan W. Larsen
        Pages 379-416
      3. Richard L. Schowen
        Pages 417-428
    6. Targeting

      1. Roger A. Rajewski, Michelle P. McIntosh
        Pages 429-445
      2. Vincent (F.M.H.) de Groot
        Pages 447-506
      3. Peter D. Senter, Damon L. Meyer
        Pages 507-524
      4. Kenneth D. Bagshawe
        Pages 525-540
      5. Mark D. Erion
        Pages 541-572
      6. Bradley D. Anderson
        Pages 573-651

About this book


Prodrugs are substances administered in an inactive form that is then metabolized in the body in vivo into the active compound. The rationale behind administering prodrugs is to optimize absorption, distribution, metabolism, and excretion of these drugs. Since first described in the 1950s, prodrugs continue to be a fertile area of research. There are a number of small pharmaceutical/biotech companies dedicated to using prodrugs for the delivery of older but problematic drugs as well as to developing broad-based prodrug technologies for application to new and future drugs. These volumes represent a comprehensive guide to prodrugs and will guide the reader through the current status of the prodrug concept and its many applications and to highlight its many successes in overcoming formulation and delivery of problematic drugs.


Challenges Prodrugs Rewards Stella dynamics metabolism

Editors and affiliations

  • Valentino J. Stella
    • 1
  • Ronald T. Borchardt
    • 1
  • Michael J. Hageman
    • 2
  • Reza Oliyai
    • 3
  • Hans Maag
    • 4
  • Jefferson W. Tilley
    • 5
  1. 1.University of KansasLawrenceUSA
  2. 2.Bristol-Myers Squibb CompanyPrincetonUSA
  3. 3.Gilead SciencesFoster CityUSA
  4. 4.Roche Palo Alto, LLCPalo AltoUSA
  5. 5.Hoffmann-La Roche, Inc.NutleyUSA

Bibliographic information

  • DOI
  • Copyright Information American Association of Pharmaceutical Scientists 2007
  • Publisher Name Springer, New York, NY
  • eBook Packages Biomedical and Life Sciences
  • Print ISBN 978-0-387-49782-2
  • Online ISBN 978-0-387-49785-3
  • About this book